HYPofractionated Adjuvant RadioTherapy in 1 versus 2 weeks in high-risk patients with breast cancer (HYPART): a non-inferiority, open-label, phase III randomised trial

HYPofractionated Adjuvant RadioTherapy in 1 versus 2 weeks in high-risk patients with breast cancer (HYPART): a non-inferiority, open-label, phase III randomised trial

Abstract Background Breast cancer is the most common cancer in women. Radiotherapy is an important part of breast cancer treatment after surgery. Breast cancer radiotherapy is usually delivered in 3–5 weeks. This is a long duration for women with breast cancer to stay away from the family and work....

Full description

Bibliographic Details
Main Authors: Budhi Singh Yadav, Divya Dahiya, P. Kannan, Shikha Goyal, Ishita Laroiya, Santhosh Irrinki, Ngangom Robert Singh, Reena Sharma
Format: Article
Language:English
Published: BMC 2024-01-01
Series:Trials
Subjects:
Breast cancer
Radiotherapy
Hypofractionation
Acute toxicity
Late toxicity
Recurrence
Online Access:https://doi.org/10.1186/s13063-023-07851-7

Internet

https://doi.org/10.1186/s13063-023-07851-7

Similar Items